DBP International AB: positive response for SI-053 from Competent Authority in the Netherlands has been received
Double Bond Pharmaceutical International AB (publ) ("DBP") takes another step towards the start of phase 1 multinational multicentral clinical trial of its front-line product SI-053 in patients with glioblastoma – positive response from Competent Authority in the Netherlands has been received. As previously reported the Clinical Trial Application (EC/CA submission) was sent in the Netherlands. Today DBP received a positive response from the Competent Authority in the Netherlands, Centrale Commissie Mensgebonden Onderzoek, which did